Gujarat Themis Biosyn Performance
- Today's Low
- ₹353
- Today's High
- ₹365
- 52 Week Low
- ₹225
- 52 Week High
- ₹479
- Open Price₹365
- Previous Close₹0
- Volume79,547
- 50 DMA₹339.13
- 100 DMA₹340.64
- 200 DMA₹340.61
Gujarat Themis Biosyn Chart
Investment Returns
- Over 1 Month + 7.2%
- Over 3 Month + 6.36%
- Over 6 Month -15.55%
- Over 1 Year + 9.64%
Smart Investing Starts Here Start SIP with Gujarat Themis Biosyn for Steady Growth!
Gujarat Themis Biosyn Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 81.4
- PEG Ratio
- -8.8
- Market Cap Cr
- 3,891
- P/B Ratio
- 14.1
- Average True Range
- 19.41
- EPS
- 4.39
- Dividend Yield
- 0.2
- MACD Signal
- 16.68
- RSI
- 52.45
- MFI
- 66.75
Latest Stock News Updates
Pharmaceuticals company Gujarat Themis Biosyn announced Q3FY26 results Revenue: Rs 4,336.82 lakh against Rs 3,951.98 lakh during Q3FY25, change 10%. PBT: Rs 1,687.34 lakh against Rs 1,740.04 lakh during Q3FY25, change -3%. PAT: Rs 1,246.46 lakh against Rs 1,297.23 lakh during Q3FY25, change -4%. EPS: Rs 1.14 for Q3FY26. Result PDF
- Trendlyne
- 3 months 2 weeks ago
Pharmaceuticals company Gujarat Themis Biosyn announced Q4FY23 & FY23 results: Q4FY23: Revenue from Operations stood at Rs 28.17 crore in Q4FY23, as against Rs 28.76 crore in Q4FY22 EBITDA for the quarter was Rs 14.93 crore as against Rs 13.08 crore in Q4FY22, increase of 14.12%. EBITDA Margin stood at 52.98%, up by 751 bps Q4FY23 PAT stood at Rs 11.69 crore as against profit of Rs 9.79 crore in Q4FY22 EPS for the quarter stood at Rs 8.05 FY23: Revenue from Operations stood at Rs 148.97 crore in FY23, vs Rs 114.85 crore in FY22, up 29.71% EBITDA for FY23 was Rs 74.22 crore as against Rs 58.05 crore in FY22, increase of 27.86% EBITDA Margin stood at 49.82% FY23 PAT stood at Rs 57.97 crore as against PAT of Rs 43.62 crore in FY22 EPS for the year stood at Rs 39.90 Result PDF
- Trendlyne
- 3 years ago
Pharmaceutical company Gujarat Themis Biosyn announced Q2FY23 results: Q2FY23 vs Q2FY22: Revenue from operations stood at Rs 47.7 crore in Q2 FY23, as against Rs 35.1 crore in Q2 FY22, rise of 36.1% EBITDA for the quarter was Rs 24.4 crore as against Rs 18.5 crore in Q2 FY22, an increase of 32.3% - EBITDA Margin stood at 51.2% Q2 FY23 Profit stood at Rs 18.7 crore as against profit of Rs 13.8 crore in Q2 FY22 EPS for the quarter stood at Rs 12.87 H1FY23 vs H1FY22: Revenue from operations stood at Rs 92.6 crore in H1 FY23, as against Rs 67.5 crore in H1 FY22, rise of 37.3% EBITDA for the six months was Rs 47.2 crore as against Rs 35.2 crore in H1 FY22, an increase of 34.2% - EBITDA Margin stood at 50.9% H1FY23 Profit stood at Rs 36.5 crore as against a profit of Rs 26.7 crore in H1 FY22 EPS for the period stood at Rs 25.10 Result PDF
- Trendlyne
- 3 years 6 months ago
Gujarat Themis Biosyn Financials
Gujarat Themis Biosyn Technicals
EMA & SMA
- Bearish Moving Average 9
- Bullish Moving Average 7
- 20 Day
- ₹357.45
- 50 Day
- ₹339.13
- 100 Day
- ₹340.64
- 200 Day
- ₹340.61
Resistance and Support
- R3 368.33
- R2 364.87
- R1 360.98
- S1 353.63
- S2 350.17
- S3 346.28
Gujarat Themis Biosyn Corporate Actions - Bonus, Splits, Dividends
About Gujarat Themis Biosyn
- NSE Symbol
- GUJTHEM
- BSE Symbol
- 506879
- Managing Director
- Dr. Sachin D Patel
- ISIN
- INE942C01045
Similar Stocks to Gujarat Themis Biosyn
Popular Stocks
Gujarat Themis Biosyn FAQs
Gujarat Themis Biosyn share price is ₹357 As on 22 May, 2026 | 05:20
The Market Cap of Gujarat Themis Biosyn is ₹3891.2 Cr As on 22 May, 2026 | 05:20
The P/E ratio of Gujarat Themis Biosyn is 81.4 As on 22 May, 2026 | 05:20
The PB ratio of Gujarat Themis Biosyn is 14.1 As on 22 May, 2026 | 05:20
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.